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Abstract- A new expeditious preparation of homochiral (-)-1-azafagomine, and (+)-5-epi-
1-azafagomine has been devised. Stoodley´s diastereoselective cycloaddition of dienes 
bearing a 2,3,4,6-tetraacetyl glucosyl chiral auxiliary to 4-phenyl-1,2,4-triazole-3,5-dione, 
was merged with Bols protocol for functionalizing alkenes into molecules bearing a 
glucosyl framework. Homochiral (+)-5-epi-1-azafagomine was synthetized for the first 
 2 
time. Partial reductive cleavage of the phenyltriazolidinone moiety afforded new 
homochiral 1-N-phenyl carboxamide derivatives of 1-azafagomine. Both enantiomers of 
these derivatives were synthetized and tested, displaying a very good enzymatic 
inhibition towards baker´s yeast α-glucosidase. The molecular recognition mechanism of 
the 1-N-phenyl carboxamide derivative of 1-azafagomine by α-glucosidase from baker´s 
yeast was studied by molecular modelling. The efficient packing of the aromatic ring of 
the 1-N-phenyl carboxamide moiety into a hydrophobic sub-site (pocket) in the enzyme´s 
active site, seems to be responsible for the improved binding affinity in relation to 
underivatized (-)1-azafagomine and (+)1-azafagomine.  
 
Introduction  
The synthesis of iminosugars is receiving an increasing interest because many of these 
structures are biological tools and potential therapeutics. The first iminosugar medicine 
registered was miglitol, (Glyset, PHARMACIA and UPJOHN).1 The biological properties 
of iminosugars arise from their interference with glycosidases, the natural carbohydrate 
degrading enzymes, and with carbohydrate recognizing receptors spread in all living 
organisms. 1-Deoxynojirimycine (1) is a natural iminosugar resembling the structure of 
glucose. The biological activity of this compound seems to be dependent on its 
conjugated ammonium form mimicking the transition state for glycoside cleavage.2 Bols 
and co-workers have demonstrated that (-)-1-azafagomine (2) is a potent competitive 
inhibitor of almond β-glucosidase (Ki= 0.32 µM), yeast α-glucosidase (Ki= 6.9 µM) and 
isomaltase (Ki= 0.27 µM).3 On the other hand, racemic (±)-5-epi-1-azafagomine (3), was 
found to be a much weaker glycosidase inhibitor of almond β-glucosidase (Ki= 137 µM) 
and E. coli β-galactosidase (Ki= 149 µM) (Figure 1).4 5-epi-1-Azafagomine  (3), as far as 
we could find, was previously unknown in any of the enantiomeric pure forms.  
 
NH
NH
OH
HO
HO
(-)-1-Azafagomine (2)
NH
NH
OH
HO
HO
(±)-5-epi-1-Azafagomine (3)
Figure 1 Structure of some known iminosugars
NH
HO
HO
OH
(+)-1-Deoxynojirimycine (1)
OH
 
 
 3 
The synthesis of homochiral (-)-1-azafagomine (2) was accomplished by Bols and co-
workers through a synthetic sequence based on the Diels-Alder cycloaddition to 4-
phenyl-1,2,4-triazole-3,5-dione (PTAD) 4 to achiral dienes: 2,4-pentadienoic acid, methyl 
2,4-pentadienoate and 2,4-pentadienol (5).4 The racemic cycloadduct 6 obtained from 
2,4-pentadienol and PTAD was resolved by lipase-mediated transesterification. The 
olefin portion of each enantiomer´s precursor of 2 was oxidized to oxirane and further 
opened under highly acidic conditions to yield the glucosyl framework of 1-azafagomine, 
compound 7. After hydrazinolysis, both enantiomers of 1-azafagomine were obtained in 
9% total yield5 (Scheme 1). Osmilation of the double bond on the racemic cycloadduct 6, 
led to racemic diol 8, which after hydrazinolysis gave 5-epi-1-azafagomine (3). Bols3 also 
achieved the synthesis of (-)-1-azafagomine (2) from relatively expensive L-xylose in 6 
steps. L-2,3,5-Tribenzyl xylofuranose was isolated as an intermediate after 3 steps with 
no explicit yield. 1-Azafagomine was then isolated in 37% overall yield from this 
intermediate.6,7  
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Alternatives to the enzymatic resolution of racemic adducts of type 6 are desirable for 
the production of chiral synthons for further elaboration into homochiral compounds. 
Stoodley in the nineties combined 2,4-pentadienoates, bearing a tetraacetyl glucosyl 
chiral auxiliary in the position 1, compound 9a, with PTAD to obtain cycloadduct 10 in 70 
% yield and in a high degree of diastereo-selectivity (Scheme 2).8,9 The chemistry of 
cycloadduct 10 had been pushed forward for the synthesis of dehydropiperazic acid, a 
non-proteinogenic amino acid constituent of antrimycins-linear heptapeptides with 
antitubercular activity.10 Lately, dienes bearing oxazolidinone chiral auxiliary were 
combined with PTAD to generate (S)-piperazinic acid.11 To the best of our knowledge, 
nobody has merged the Stoodley cycloaddition entry into chiral alkenes of type 11 with 
Bols´s olefin functionalization methodology for synthetizing enantiopure iminosugars.  
 
 Results and Discussion 
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 New synthetic sequence for preparing homochiral (-)-1-azafagomine, and (+)-
5-epi-1-azafagomine.  
In this paper we report a new synthetic route for obtaining homochiral (-)-1-azafagomine 
(-)-2, and (+)-5-epi-1-azafagomine  (+)-3 from chiral alkene (-)-11. (Scheme 2) 
 
N
N
CO2Et
N Ph
O
O
vii)
N
N N Ph
O
O
HO
HO
v)
OH
HO
HO
N
N
OH
HO
HO
iv)
N
N
CO2Et
N Ph
O
O
N
N
CO2Et
N Ph
O
O
O N
N
CO2Et
N Ph
O
O
HO
HO
(-)-11 12 13
N
N
CO2Et
OR*
N Ph
O
O
R*= O
OAc
OAc
OAc
OAc
10
Scheme 2 - i) Et3SiH, TFA, DCM, 5h, rt, 61 %; ii) oxone, CF3COCH3, NaHCO3, CH3CN/H2O (3.5:2),
24h, 65% iii) H2O, H2SO4 (exc.), reflux, 8h, 52%; iv) NaBH4 (3 eq.), EtOH, 3d, rt, 59 %; v)
NH2NH2.H2O, 100 ºC, 18h, 68 % (-)-2; 64 % (+)-3; vi) OsO4, NMO, Acetone:H2O (2:1), 5d, rt, 79 %; vii) 
NaBH4 (3 eq.), EtOH, 3d, rt, 52%.
i) ii) iii)
OR*9a
CO2Et
v)
N
O
O
Ph
15
(-)-2
vi)
(+)-3
1614
4+
 
Cycloadduct 10 was submitted to reductive cleavage with triethylsilane, according to 
Stoodley´s protocol, to generate known compound (-)-11.9 Treatment of 11 with 
oxone/trifluoroacetone in the presence of NaHCO3 at room temperature for 1 day, 
generated a 3:1 mixture of oxiranes as reported previously by Bols for his racemic 
compounds.4 Selective crystallization afforded the major isomer 12 in 65 % yield. 
Opening of oxirane 12 was achieved with total regio- and stereo-selectivity by refluxing 
in aqueous H2SO4 giving 13. Osmilation of compound 11 produced cis-diol 14 with total 
stereo-selectivity. Selective reduction of trans-diol 13 and cis-diol 14 with NaBH4, gave 
respectively triols 15 and 16. These compounds were further treated with hydrazine 
under reflux to produce the target compounds: (-)-1-azafagomine (2) in 14 % overall 
yield and (+)-5-epi-1-azafagomine (3) in 26 % overall yield, from alkene (-)-11 (Scheme 
2). While (-)-1-azafagomine 2 is a known compound, (+)-5-epi-1-azafagomine 3 was 
obtained enantiomerically pure for the first time. Pure (+)-5-epi-1-azafagomine displays 
NMR spectra compatible with the data published for the racemic compound 3. The 
specific optical rotation obtained for (+)-5-epi-1-azafagomine is [αD = + 65 (H2O, c = 
0.70)]. The specific optical rotation value measured for (-)-1-azafagomine [αD = - 20 
(H2O, c = 0.85)] differs from the one reported in lit [αD = -9.8 (H2O, c = 0.85)].3  
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 New synthetic sequence for preparing homochiral 1-N-phenyl carboxamide 
derivatives of 1-azafagomine  (+)-22 and (-)-22 
Stoodley was able to prepare the precursors of (-)-22 and (+)-22 from (E,E)-diene 9b 
and (E,Z)-diene 17 respectively by the method described in scheme 3.9 
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Scheme 3 - Stoodley´s synthetic sequence for precursors related to compounds (-)-2, (-)-22 and (+)-22  
 
(E,E)-Diene 9b was isolated in 70 % yield and (E,Z)-diene 17 in 14 % yield. Applying 
Still´s olefination the yield of the (E,Z)-diene could be improved to 36 %.9 (Scheme 3) 
Having in mind the shortcomings in the synthesis of compound 17, epimerization of 
compound 10 obtained by Stoodley´s method was tried in various conditions: i) 
triethylamine in MeOH, ii) NaN3 in MeOH, iii) triethylamine / p-chlorothiophenol in MeOH. 
(Scheme 4) When triethylamine was the sole reagent, isolation of compound 18 was 
difficult, due to competing elimination of glucosyl moiety giving the 1,3-diene compound. 
The same applied for the attempt with NaN3. The mixture of triethylamine / p-
chlorothiophenol afforded after 40 min of reaction 88 % yield of compound 18. This 
represents an important achievement concerning the synthesis of compound 18. 
Extending the reaction time, a Michael addition of p-chlorothiophenol occurs leading to 
compound (±)-19. (Scheme 4)  
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The structure of compound 18 was unambiguously confirmed by X-ray crystallography. 
(Figure 2) 
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Figure 2 ORTEP view of compound 18 
 
Reduction of the ester and urea groups in the triazolidinone moiety 
i) in the synthesis of compound (-)-21 
 When compound (-)-11 was treated with 7 equivalents of freshly opened LiAlH4, a new 
compound formed, according to 1H NMR spectroscopy. If the LiAlH4 was not strictly 
fresh a mixture of two compounds was observed on the 1H NMR spectrum. Further 
treatment with LiAlH4 converted the mixture into the same compound observed before. 
The structure of the intermediate in the reduction process was determined by X-ray 
crystallography and identified as compound 20 (Figure 3). 
 
Figure 3 ORTEP view of compound 20 
 
Knowledge of the bridged structure of compound 20, allowed us to propose a plausible 
mechanism for its formation and the formation of compound 21. (Scheme 5) 
 7 
Scheme 5 - i) LiAlH4 (7 eq.)a), THF, 4h, 0 ºC -> rt, 86 %; ii) LiAlH4 (15 eq.)b), THF, 4, 0 ºC -> rt, 48 %
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The Schiff salt initially formed by reduction of one of the carbonyl groups is trapped by 
internal nucleophilic attack of the alcohol function. A large excess of hydride was 
necessary to cleave intermediate 20 to final product 21. Compounds 20 and 21 display a 
major difference in their 13C NMR spectra: a peak at δC = 86.3 ppm, assigned to the 
methylene attached to the oxygen and nitrogen atoms in compound 20 is not apparent in 
the 13C NMR spectrum of compound 21.  
 
ii) in the synthesis of compounds (-)-22 and (+)-22 
Attempted epoxidation of compound 21 was unsuccessful leading to a complex mixture. 
As an alternative, compound (-)-13 was subjected to treatment with LiAlH4 in THF to give 
compound (-)-22. The synthesis of compound (+)-22 was obtained from 18, (Scheme 4) 
by reductive cleavage of the glucosyl moiety to give (+)-11 followed by the functional 
group transformation described in scheme 6. 
The enantiopure compounds (-)-1-N-phenyl carboxamide 1-azafagomine (-)-22 and (+)-
1-N-phenyl carboxamide 1-azafagomine (+)-22 were obtained following the same 
sequence of reactions in 29 % and 10 % overall yield starting from compounds 10 and 
18 respectively.  
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 1-N-Phenyl carboxamide derivatives of 1-azafagomine: new leads for the 
synthesis of potent α-glycosidase inhibitors  
A structure-activity relationship study of a series 2-N-alkylated 1-azafagomines as 
glycosidase inhibitors, revealed that these compounds are better β-glycosidase inhibitors 
than α-glycosidase inhibitors. Moreover, the inhibition constant (Ki) was found to be 
dependent on the chain length. The best results have been obtained with the N-
propylphenyl derivative 23 (Ki =0.032 µM) and the N-hexyl derivative 24 (Ki =0.055 µM).12 
(Table 1) 
 
 
Table 1. Ki values (µM) for the inhibition of α- and β-glucosidases by compounds 22 and 
other azasugars at different pH values. 
Compound α-glucosidase 
(bakers’ yeast) 
β-glucosidase 
(almonds) 
α/β-
selectivity 
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(-)-22 3.36[b] 
____[c,d] 
14.7[b] 
67.4[c] 
 
0.23 
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N
O
N
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OH 	  
(+)-22 10.6[b] 
____[c,d] 
25.2[b] 
90.0[c] 
0.42 
[a] pH 6.8; [b] pH 7.0; [c] pH 5.0; [d] enzyme inactive 
 
The N-propylphenyl derivative 23 is around an order of magnitude more effective as β-
glucosidase inhibitor than (-)-1-azafagomine 2. On the other hand, derivative 23 is a 
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much weaker inhibitor of α-glucosidase than its parent compound (2), making compound 
23 a potent inhibitor selective for β-glucosidase.12 
The most striking results of the inhibition studies with the 1-N-phenyl carboxamide 
derivatives of 1-azafagomines 22 are Ki towards α-glucosidase substantially lower than 
the N-propylphenyl derivative 23. Compound (-)-22 displaying the same stereochemistry 
as (-)-1-azafagomine 2 is around two times more active, while its isomer (+)-22 is slightly 
less active. Both enantiomers of compound 22 display lower activity towards β-
glucosidase than their parent compound 2 and the N-propylphenyl derivative. A 
moderate α/β selectivity was observed for compounds 22. The low Ki values obtained for 
compounds 22 towards α-glucosidase suggests an efficient recognition mechanism 
between both enantiomers and the enzyme. The levorotatory isomer was slightly more 
active than the dextrorotatory isomer. (Table 1) This observation is in contrast with the 
results reported by Bols who demonstrated that (-)-1-azafagomine is the active 
enantiomer while (+)-1-azafagomine is virtually inactive towards the same α-glucosidase 
that was used in this study.3  
The yeast α-glucosidase enantioselective discrimination towards (+)-22 and (-)-22 was 
studied using molecular docking methodologies. This enzyme, as well as the S. 
cerevisiae enzyme used for the homology modelling13, belongs to the glycoside 
hydrolase family 13 (GH 13). This family of retaining glucosidases is characterized by 
strong recognition of the a glucoside moiety of synthetic p-nitrophenyl glucosides and 
heterogeneous substrates such as sucrose, while being inactive towards hydration of D-
glucal and the hydrolysis of p-nitrophenyl α-2-deoxyglucosides.14,15 The active site 
structure on Figure 4 illustrates that this enzyme retains the nucleophile aspartate 214 
and the catalytic residues glutamate 276 and aspartate 349. Our theoretical binding 
affinity estimate for (+)-22 and (-)-22 against yeast α-glucosidase are of -7.8 and -7.5 
kcal/mol, respectively. The binding affinity free energy difference between the two 
enantiomers is within the docking standard error (~2 kcal/mol), and consequently, it 
suggests, low enantiomeric discrimination of (+)-22 and (-)-22. However, our 
experimental Ki data (Table 1) indicates a preferential binding of (-)-22 when compared 
to (+)-22. This discrepancy can be explained by the lack of mobility of enzyme to 
reorganize during the docking experiments, and consequently, to properly recognize the 
most potent enantiomeric compound, (-)-22. Despite of this, the observation of the 
binding pose of both enantiomers 22 provides a structural explanation of their binding 
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mechanism (Figure 4) and a rational approach for their future improvement. These 
complexes correspond to lowest binding energy pose. They belong to the most 
populated cluster of docking solutions, 7 and 8 docking poses out of 20, respectively for 
each enantiomer. 
 
 
Figure 4. Structure of the lowest binding free energy complexes between yeast α-
glucosidase binding site and the enantiomers of compound 22: A) (+)-22 and B) (-)-22. 
Figure is rendered with Corey-Pauling-Koltun (CPK) colouring scheme. Selected side-
chain residues of the yeast α-glucosidase binding pocket are rendered in sticks and 
labeled with the 3-letter aminoacid code name and sequence residue number. 
Compounds are rendered in ball-and-stick style. 
 
The α-glucosidase enzyme active site is characterized by two distinct regions, a highly 
polar region due to the presence of histidine 348, glutamate 276, aspartate 68, 214, 349, 
arginine 212, 439; and a hydrophobic pocket flaked by phenylalanine 157, 177, leucine 
218 and alanine 278 (Figure 4). The binding affinity between the two 22 enantiomers 
and yeast α-glucosidase is the result of several strong hydrogen bonding interactions 
between two hydroxyl and amine groups of (+)-22 and (-)-22 with aspartate 68, 214, 
349, arginine 212, 439 and histidine 348 of the α-glucosidase enzyme active site. The 
highlighted non-bonded interactions of (-)-22 with histidine 348, arginine 439 and 
aspartate 68 are shorter for this enantiomer when compared to (+)-22, suggesting a 
stronger interaction of (-)-22 with the enzyme. Based on these observations, the 
molecular modelling study suggests that the binding affinity can be improved either by: 
a) increasing the length of the N-phenyl-1-carboxamide moiety or, b) introducing 
 11 
donor/acceptor moieties on the p- position of the aromatic ring. These avenues are 
being currently pursued in order to improve the binding affinity, and ideally selectivity. 
 
Conclusions 
In this paper we report the preparation of homochiral 1-azafagomine (-)-2, and (+)-5-epi-
1-azafagomine (+)-3. The synthetic route devised merges Stoodley diastereo-selective 
Diels-Alder cycloaddition methodology with Bols protocol for functionalizing alkenes into 
molecules bearing sugar-like frameworks. Novel 1-N-phenyl carboxamide derivatives of 
1-azafagomine 22 were obtained in enantiomeric pure forms. The epimerization of 
cycloadduct 10 revealed to be the key step on the synthesis of the dextrorotatory 
compound 22. This methodology represents an advantageous alternative to other more 
conventional approaches for obtaining enantiopure (+)-2 (not isolated in this work) and 
its derivatives (e.g. N-phenyl carboxamides). Compounds 22 were tested as inhibitors 
against α- and β-glucosidases. Both enantiomeric forms of 22 are potent inhibitors of α-
glucosidase in contrast to the current wisdom that only (-)-2 enantiomer of 1-
azafagomine is active towards α- and β-glucosidase. The low Ki value determined 
towards α-glucosidase inhibition is particularly relevant comparing to its analogue N-
propylphenyl azafagomine, the compound in table 1 with a closer side chain length. The 
molecular recognition mechanism between the enatiomeric compounds 22 and the α-
glucosidase studied by molecular modelling has shown that the aromatic group is 
accommodated in a hydrophobic pocket of the enzyme binding site with polar 
characteristics at its end. This evidence has provided further clues for improving the 
binding affinity and, possibly, the α/β selectivity, by increasing the length of the N-
carboxamide moiety and the introduction of donor/acceptor hydrogen bond groups on 
the aromatic ring.  
The results of this study suggest that 1-N-phenyl carboxamide derivatives of 1-
azafagomine are potential new leads for the synthesis of potent α-glycosidase inhibitors.  
 
Experimental Section 
General: Solvents were distilled under anhydrous conditions. The (S)-ethyl 2-phenyl-
2,4,9-triazabicyclo[4.3.0]non-6-ene-1,3-dione-5-carboxylate (-)-11 was obtained 
according to Stoodley´s protocol for the (S)-methyl carboxylate derivative; 2,3,4,6-tetra-
O-acetyl-α-D-glucopyranosyl bromide (ABG) was prepared according lit.16, potassium 3-
hydroxypropenal17 was combined to ABG18 followed by addition of tributylphosphorane.9 
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The diene obtained was subjected to 4-phenyl-1,2,4-triazole-3,5-dione (PTAD) to obtain 
the adduct 10. The glucose moiety was removed by reduction with triethylsilane.10 
Compound 7 (R=CH2OH) was obtained according to lit.4 Functionalization of the double 
bond was obtained by osmilation with OsO4 in acetone/water or with oxone, 
trifluoromethylacetone, in the presence of NaHCO3 and aqueous acetonitrile. Reduction 
of the oxazolidinone was done either with freshly opened LiAlH4 1M in THF, or with long 
term open bottles (over a month) of LiAlH4 1M in THF. All reagents were purchased and 
used without further purification. Glassware was dried prior to use. Compounds were 
purified by dry flash chromatography, using silica 60, <0,063 mm and water pump 
vacuum or by flash-chromatography, using silica 60A 230-400 Mesh as stationary 
phases. TLC plates (Silica Gel 60 F254) were visualized either at UV lamp or in I2. 
 
 
Synthesis of ethyl 5-(2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyloxy)-2,4-
pentadienoate 9 
To a solution of ethyl tributyl phosphorane9 (3.37 g; 11.70 mmol) in DCM (15 mL) was 
added 3-(2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyloxy)-1-propenal17 (1.32 g; 3.42 
mmol), the orange solution formed was stirred at rt for 24h. The solvent was evaporated 
giving an oil subjected to dry-flash chromatography (petroleum ether: diethyl ether; 
gradient of polarity) (9, 1.17 g; 63 %). [α]D20 +27.0º (c = 1, CH2Cl2). νmax(Nujol, cm-1) 
2955, 2934, 1736, 1698, 1635. 1H NMR (δH, 300 MHz, CDCl3) 1.27 (3H, t, J 7.2 Hz, 
CH3), 2.01, 2.03, 2.04, 2.08 (12H, 4×s, 4× CH3CO2), 3.81 (1H, ddd, J 9.0, 6.0, 3.0 Hz, H-
5’), 4.13 (1H, dd, J 9.0, 3.0 Hz, H-6’), 4.18 (2H, q, J 6.0 Hz, CH2), 4.26 (1H, dd, J 12.0, 
3.0 Hz, H-6’), 4.87 (1H, d, J 9.0 Hz, H-1’), 5.08-5.29 (3H, m, H-2’ + H-3’ + H-4’), 5.78 
(1H, d, J 15.0 Hz, H-2), 5.90 (1H, t, J 12.0 Hz, H-4), 6.81 (1H, d, J 12.0 Hz, H-5), 7.20 
(1H, dd, J 15.0, 12.0 Hz, H-3) ppm. 13C NMR (δC, 75.5 MHz, CDCl3) 14.2 (CH3), 20.5, 
20.5, 20.7 (CH3CO2), 60.1 (CH2), 61.6 (C-6’), 67.8, 70.6, 72.3 (C-2’, C-3’, C-4’), 72.4 (C-
5’), 99.7 (C-1’), 110.1 (C-4), 118.7 (C-2), 140.9 (C-3), 152.6 (C-5), 167.0 (C=O ester), 
169.1, 169.2, 170.1, 170.5 (CH3CO2) ppm. 
 
Synthesis of (5S,8S)-ethyl 8-(2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyloxy)-2-
phenyl-2,4,9-triazabicyclo[4.3.0]non-6-eno-1,3-dione-5-carboxylate 10 
To a solution of diene 9 (1.31 g; 2.86 mmol) in DCM (15 mL) was added 4-phenyl-1,2,4-
triazole-3,5-dione (0.50 g; 2.86 mmol), giving a red coloured solution that quickly lost its 
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colour. The reaction mixture was stirred for a further 30 min and then evaporated. The 
residue was tritured with ethyl ether. A white solid was formed and filtered giving the title 
compound (10, 1.302 g; 70 %). [α]D20 +23,8º (c = 1, CH2Cl2). νmax(Nujol, cm-1) 2954, 
2853, 1743, 1620, 1635, 1218. 1H NMR (δH, 300 MHz, CDCl3) 1.35 (3H, t, J 6.0 Hz, 
CH3), 2.00, 2.01, 2.02, 2.04 (12H, 4×s, 4×CH3CO2), 3.87 (1H, ddd, J 12.0, 6.0, 3.0 Hz, 
H-5’), 4.05 (1H, dd, J 12.0, 3.0 Hz, H-6’), 4.27 (1H, dd, J 15.0, 9.0 Hz, H-6’), 4.34 (2H, 
dq, J 7.2, 1.2 Hz, CH2), 5.01 (2H, m, H-5 + H-2’), 5.09 (1H, t, J 9.9 Hz, H-4’), 5.19-5.26 
(2H, m, H-3’ + H-1’), 6.06-6.12 (2H, m, H-8 + H-7), 6.19-6.26 (1H, m, H-6), 7.39-7.56 
(5H, m, Ph) ppm. 13C NMR (δC, 75.5 MHz, CDCl3) 14.0 (CH3), 20.5, 20.6, 20.6 
(CH3CO2), 56.7 (C-5), 61.5 (C-6’), 62.9 (CH2), 67.8 (C-4’), 71.0 (C-2’), 72.1 (C-5’), 72.8 
(C-3’), 74.6 (C-8), 97.2 (C-1’), 123.3 (C-7), 124.9 (C-6), 125.4 (C-H, Ph), 128.5 (C-H, 
Ph), 129.2 (C-H, Ph), 130.7 (Cq, Ph), 150.2 (C=O), 151.4 (C=O), 165.6 (C=O ester), 
169.4, 169.4, 170.2, 170.7 (CH3CO2) ppm. HRMS (FAB): Calcd for C29H33N3O14, 
648.2041; Found, 648.2041. 
 
Synthesis of (S)-ethyl 2-phenyl-2,4,9-triazabicyclo[4.3.0]non-6-ene-1,3-dione-5-
carboxylate (-)-11 
To a solution of the cycloadduct 10 (1.31 g; 2.03 mmol) in DCM (20 mL) was added 
triethylsilane (12.7 mL; 0.78 mol) and trifluoroacetic acid (12.7 mL; 0.17 mol). The 
resulting yellow suspension was kept under stirring at rt for 5 h. The solvent was 
removed under vacuum and the residue re-dissolved in DCM (30 mL). The solution was 
washed with aq. sat. sol. of NaHCO3 (3×50 mL) and water (50 mL). The combined 
organic layers were dried over magnesium sulphate, filtered and the solvent evaporated. 
From the residual oil crystallized a white solid that was washed with diethyl ether and 
proved to be the title compound ((-)-11, 0.313 g; 51 %). [α]D20 -311.0º (c = 2.15, CH2Cl2); 
m.p. 140-142 ºC. νmax(Nujol, cm-1) 2954, 2923, 1742, 1714. 1H NMR (δH, 300 MHz, 
CDCl3) 1.29 (3H, t, J 7.2 Hz, CH3), 3.99-4.06 (1H, dm, H-8), 4.25 (2H, q, J 7.2 Hz, CH2), 
4.38-4.45 (1H, dm, H-8), 5.09-5.12 (1H, m, H-5), 6.05-6.16 (2H, m, H-6 + H-7), 7.38-7.57 
(5H, m, Ph) ppm. 13C NMR (δC, 75.5 MHz, CDCl3) 14.1 (CH3), 43.1 (C-8), 55.9 (C-5), 
62.4 (CH2), 119.7 (C-6 or C-7), 123.3 (C-6 or C-7), 125.6 (C-H, Ph), 128.2 (C-H, Ph), 
129.1 (C-H, Ph), 131.1 (Cq, Ph), 152.3 (C=O), 153.3 (C=O), 166.7 (C=O ester) ppm. EA 
Calcd for C15H15N3O4, C, 59.79 %; H, 5.02 %; N, 13.95 %; Found, C, 59.90 %; H, 4.93 
%; N, 13.86 %. 
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Synthesis of (R)-ethyl 2-phenyl-2,4,9-triazabicyclo[4.3.0]non-6-ene-1,3-dione-5-
carboxylate (+)-11 
To a solution of the cycloadduct 18 (1.03 g; 1.59 mmol) in DCM (25 mL) was added 
triethylsilane (9.85 mL; 0.78 mol) and trifluoroacetic acid (9.85 mL; 0.17 mol). The 
resulting yellow solution was kept under stirring at rt for 5 h. The solvent was removed 
under vacuum and the residue re-dissolved in DCM (25 mL). The solution was washed 
with aq. sat. sol. of NaHCO3 (3×25 mL) and water (25 mL). The combined organic layers 
were dried over magnesium sulphate, filtered and the solvent evaporated. From the 
residual oil crystallized a white solid that was washed with diethyl ether and proved to be 
the title compound ((+)-11, 0.292 g; 61 %). [α]D20 +370.0º (c = 1, CH2Cl2). 
 
Synthesis of (5S,6R,7S)-ethyl 6,7-epoxy-2-phenyl-2,4,9-triazabicyclo[4.3.0]nonano-
1,3-dione-5-carboxylate (-)-12 
To a solution of compound (-)-11 (0.48 g; 1.59 mmol) in acetonitrile (28.0 mL), water 
(16.0 mL) and 1,1,1-trifluoracetone (3.21 mL), was added solid NaHCO3 (2.44 g; 29.02 
mmol), oxone (12.00 g; 39.04 mmol) for 20 min. at 0ºC. The mixture was stirred for 18 h. 
A new portion of solid NaHCO3 (2.44 g; 29.02 mmol) and oxone (12.00 g; 39.04 mmol) 
was added and stirred for another 4 h. Then water (100 mL) was added to the reaction 
mixture, extracted with CHCl3 (8×40 mL). The organic layers were combined and dried 
with magnesium sulphate. After removal of the solvent and recrystallization with diethyl 
ether gave a white solid identified as the title compound ((-)-12, 0.329 g; 65 %). [α]D20 – 
238.0º (c = 0.8, CH2Cl2); m.p. 218-220 ºC. νmax(Nujol, cm-1) 2950, 2923, 1775, 1750, 
1715, 1458 , 1094, 1034. 1H NMR (δH, 300 MHz, CDCl3) 1.32 (3H, t, J 7.1 Hz, CH3), 
3.53-3.65 (2H, m, H-7 + H-8), 3.89 (1H, dd, J 5.6, 3.8 Hz, H-6), 4.19-4.40 (2H, m, CH2), 
4.47 (1H, dd, J 13.6, 1.4 Hz, H-8), 5.01 (1H, d, J 5.7 Hz, H-5), 7.33-7.51 (5H, m, Ph) 
ppm. 13C NMR (δC, 75.5 MHz, CDCl3) 14.1 (CH3), 43.0 (C-8), 49.0 (C-6), 50.1 (C-7), 54.8 
(C-5), 62.7 (CH2), 125.6 (C-H, Ph), 128.4 (C-H, Ph), 129.1 (C-H, Ph), 130.9 (Cq, Ph), 
153.3 (C=O), 153.56 (C=O), 165.6 (C=O ester) ppm. HRMS (FAB): Calcd for 
C15H16N3O5, 318.1089; Found, 318.1087. 
 
Synthesis of (5R,6S,7R)-ethyl 6,7-epoxy-2-phenyl-2,4,9-triazabicyclo[4.3.0]nonano-
1,3-dione-5-carboxylate (+)-12 
To a solution of compound (+)-11 (0.37 g; 1.21 mmol) in acetonitrile (21.1 mL), water 
(12.3 mL) and 1,1,1-trifluoracetone (2.40 mL), was added solid NaHCO3 (1.86 g; 29.02 
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mmol), oxone (9.15 g; 39.04 mmol) for 20 min. at 0ºC. The mixture was stirred for 18 h. 
A new portion of solid NaHCO3 (1.86 g; 29.02 mmol) and oxone (9.15 g; 39.04 mmol) 
was added and stirred for another 4 h. Then water (60 mL) was added to the reaction 
mixture, extracted with DCM (10×40 mL). The organic layers were combined and dried 
with magnesium sulphate. After removal of the solvent and recrystallization with diethyl 
ether gave a white solid identified as the title compound ((+)-12, 0.233 g; 60 %). [α]D20 + 
232.8º (c = 0.8, CH2Cl2). 
 
Synthesis of (5S,6R,7R)-ethyl 6,7-dihydroxy-2-phenyl-2,4,9-triazabicyclo[4.3.0] 
nonane-1,3-dione-5-carboxylate (-)-13 
To a solution of epoxide (-)-12 (0.20 g; 0.63 mmol) in water (30 mL) was added conc. 
H2SO4 (0,5 mL) and the mixture was refluxed for 8 h. After this time solid NaHCO3 (0.86 
g; 10.24 mmol) was added and the water evaporated till dryness. The residue was 
dissolved in ethyl acetate (100 mL) and washed with NaCl (50 mL). The organic phase 
was separated and the aqueous phase was extracted with ethyl acetate (100 mL). The 
organic phases were combined and dried with magnesium sulphate, filtered and 
concentrated in the rotary evaporator. The yellowish solid obtained was washed with 
diethyl ether and found to be the title compound ((-)-13, 0.110 g; 52 %). [α]D20 -22.8º (c = 
2, acetone). νmax(Nujol, cm-1) 3596-3540, 2954, 2923, 1729, 1698, 1122, 1088. 1H NMR 
(δH, 400 MHz, CDCl3) 1.24 (3H, m, CH3), 3.64 (1H, d, J 12.0 Hz, H-8), 3.95 (1H, bs, H-
7), 3.99 (1H, d, J 12.8 Hz, H-8), 4.13-4.28 (2H, m, CH2), 4.46 (1H, t, J 2.8 Hz, H-6), 4.74 
(1H, d, J 2.8 Hz, H-5), 7.38-7.50 (5H, m, Ph) ppm. 13C NMR (δC, 100 MHz, CDCl3) 13.9 
(CH3), 44.3 (C-8), 59.4 (C-5), 62.6 (CH2), 65.9 (C-7), 67.4 (C-6), 125.9 (C-H, Ph), 128.6 
(C-H, Ph), 129.3 (C-H, Ph), 131.0 (Cq, Ph), 152.1 (C=O), 154.1 (C=O), 167.3 (C=O 
ester) ppm. HRMS (FAB): Calcd for C15H18N3O6, 336.1196; Found, 336.1207. 
 
Synthesis of (5R,6S,7S)-ethyl 6,7-dihydroxy-2-phenyl-2,4,9-triazabicyclo[4.3.0] 
nonane-1,3-dione-5-carboxylate (+)-13 
To a solution of epoxide (+)-12 (0.23 g; 0.73 mmol) in water (35 mL) was added conc. 
H2SO4 (0.7 mL) and the mixture was refluxed for 10 h. After this time solid NaHCO3 
(1.42 g; 16.90 mmol) was added and the water evaporated till dryness. The residue was 
dissolved in ethyl acetate (100 mL) and washed with NaCl (50 mL). The organic phase 
was separated and the aqueous phase was extracted with ethyl acetate (3×100 mL). 
The organic phases were combined and dried with magnesium sulphate, filtered and 
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concentrated in the rotary evaporator. The yellowish solid obtained was washed with 
diethyl ether and found to be the title compound ((+)-13, 0.121 g; 49 %). [α]D20 +26.9º (c 
= 0.5, acetone).  
 
Synthesis of (5S,6R,7S)-ethyl 6,7-dihydroxy-2-phenyl-2,4,9-triazabicyclo[4.3.0] 
nonane-1,3-dione-5-carboxylate 14 
 To a solution of (-)-11 (0.30 g; 1.00 mmol) in acetone (1 mL) and water (0.5 mL) was 
added 4-methylmorpholine N-oxide (0.18 g; 1.49 mmol) and a solution of OsO4 in water 
4 % (108 mL). The mixture of stirred for 5 days. Then a aq. sol. of Na2S2O3 5 % (25 mL) 
was added to mixture and stirred for 15 min. After the solution was extracted with ethyl 
acetate (4 x 30 mL) and the organic phases were washed with water (10 mL). The 
organic phase was dried over MgSO4, filtered and concentrated to give a white solid (14, 
0.26 g; 79 %). [α]D20 -110.6º (c = 2.05, acetone). νmax(Nujol, cm-1) 3425, 1768, 1749, 
1736, 1287, 1204. 1H NMR (δH, 400 MHz, CDCl3) 1.27 (3H, t, J 7.2 Hz, CH3), 3.35 (1H, 
d, J 10.8 Hz, H-8), 3.83 (1H, ddd, J 10.0, 5.2, 2.8 Hz, H-7), 4.03 (1H, dd, J 11.6, 5.2 Hz, 
H-8), 4.24 (2H, q, J 7.2 Hz, CH2), 4.52 (1H, t, J 2.8 Hz, H-6), 4.90 (1H, d, J 3.6 Hz, H-5), 
7.40-7.49 (5H, m, Ph) ppm. 13C NMR (δC, 100 MHz, CDCl3) 14.0 (CH3), 43.2 (C-8), 60.6 
(C-5), 62.8 (CH2), 65.1 (C-7), 67.2 (C-6), 125.8 (C-H, Ph), 128.6 (C-H, Ph), 129.3 (C-H, 
Ph), 130.9 (Cq, Ph), 151.4 (C=O), 153.8 (C=O), 166.4 (C=O ester) ppm. HRMS (FAB): 
Calcd for C15H18N3O6, 336.1196; Found, 336.1195. 
 
Synthesis of (5S,6R,7R)-6,7-dihydroxy-5-hydroxymethyl-2-phenyl-2,4,9-
triazabicyclo[4.3.0] nonane-1,3-dione 15 
To a solution of the diol (-)-13 (0.07 g; 0.22 mmol) in ethanol (3 mL) was added NaBH4 
(8 mg; 0.22 mmol), under magnetic stirring at room temperature. After 1 h an aliquot was 
quenched with HCl 0.4 M, extracted with ethyl acetate, dried over magnesium sulfate 
and concentrated. 1H NMR spectrum showed that the reaction was not completed and a 
new amount of NaBH4 (8 mg; 0.22 mmol) was added and the mixture stirred for another 
4 h. The procedure was repeated with addition of NaBH4 (8 mg; 0.22 mmol). The 
reaction was quenched with aq. HCl 0.4 M (4.4 mL), the mixture stirred for 10 min and 
evaporated. The residue is dissolved in water (10 ml) and extracted with ethyl acetate (8 
x 15 mL). The organic phases were combined and dried over magnesium sulphate. 
Evaporation of the solvent gave a white solid identified as the title compound (15, 0.037 
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g; 59 %). [α]D20 -70.4º (c = 1.2, acetone). The spectroscopic data of the racemic mixture 
is reported before.4 
 
Synthesis of (5S,6R,7S)-6,7-dihydroxy-5-hydroxymethyl-2-phenyl-2,4,9-
triazabicyclo[4.3.0] nonane-1,3-dione 16 
To a solution of the diol 14 (0.224 g; 0.73 mmol) in ethanol (7 mL) was added NaBH4 
(0.083 g). The mixture was stirred at room temperature overnight. After addition of aq. 
HCl 0.4 M (15.3 mL) the mixture was stirred for 15 min. Then the solvent was removed 
under vacuum, the residue was dissolved in water (20 mL) and sat. aq. sol. of NaHCO3 
(10 mL), and extracted with ethyl acetate (14 x 25 mL). The organic layers were 
combined, dried over magnesium sulphate and concentrated. It was obtained a white 
solid identified as the title compound (16, 0.112 g; 52 %). [α]D20 - 8.0º (c = 0.75, 
acetone). The spectroscopic data of the racemic mixture is reported before.4 
 
Synthesis of ethyl (5R,8S)-8-(2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyloxy)-2-
phenyl-2,4,9-triazabiciclo[4.3.0]non-6-ene-1,3-dione-5-carboxylate 18 
To a suspension of compound 10 (0.22 g; 0.33 mmol) in methanol (5 mL) was added 4-
chorothiophenol (0.10 g; 0.68 mmol) and triethylamine at 0ºC and under magnetic 
stirring. After 40 min. the solvent was evaporated and the crude subjected to dry-flash 
chromatography (petroleum ether / ether 1:3). The product was obtained as a white solid 
(18; 0.187 g; 0.30 mmol; 88 %), m.p. 154-157 ºC. [α]D20 + 219.7º (c = 1, acetone). 
νmax(Nujol, cm-1) 2955, 2924, 1744, 1723, 1226. 1H NMR (δH, 400 MHz, CDCl3) 1.28 (3H, 
t, J 7.2 Hz, CH3), 1.88, 1.98, 2.02, 2.07 (12H, 4xs, 4xCH3CO2), 3.74-3.79 (1H, m, H-5’), 
4.15 (1H, dd, J 12.4, 2.4 Hz, H-6’), 4.23 (2H, q, J 7.2 Hz, CH2), 4.25 (1H, dd, J 12.0, 4.4 
Hz, H-6’), 4.95 (1H, dd, J 9.6, 8.0 Hz, H-2’), 5.07 (1H, t, J 10.0 Hz, H-4’), 5.15 (1H, dd, J 
5.2, 2.0 Hz, H-5), 5.18-5.23 (2H, m, H-1’+ H-3’), 5.96 (1H, d, J 4.8 Hz, H-8), 6.07 (1H, 
ddd, J 10.0, 4.4, 2.0 Hz, H-6), 6.31 (1H, ddd, J 10.0, 5.2, 0.8 Hz, H-7), 7.27-7.56 (5H, m, 
Ph) ppm. 13C NMR (δC 100 MHz, CDCl3) 14.0 (CH3), 20.5, 20.5, 20.7 (CH3CO2), 56.0 (C-
5), 61.6 (C-6’), 62.7 (CH2), 68.0 (C-4’), 71.1 (C-2’), 72.2 (C-5’), 72.6 (C-3’), 76.0 (C-8), 
99.6 (C-1’), 123.9 (C-7), 124.1 (C-6), 125.6 (C-H, Ph), 128.6 (C-H, Ph), 129.2 (C-H, Ph), 
130.8 (Cq, Ph), 151.5 (C=O), 153.4 (C=O), 166.0 (C=O ester), 169.2, 169.4, 170.1, 
170.6 (CH3CO2) ppm. EA Calcd for C29H33N3O14, C, 53.79 %; H, 5.14 %; N, 6.49 %; 
Found, C, 53.58 %; H, 5.23 %; N, 6.38 %. 
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Synthesis of (S)-N-phenyl-3-oxa-1,9-diazabicyclo[3.3.1]non-6-ene-9-carboxylate 20 
To a solution of ester (-)-11 (0.205 g; 0.68 mmol) solubilized in dry THF (13 mL) was 
added LiAlH4 1 M in THF (7 eq., 5.2 mL), from a flask containing a white deposit, at 0ºC. 
The mixture was kept under stirring for 4h at rt. The reaction was quenched with a 
sequence addition of water (1 drop), aq. NaOH 15 % (2 drops) and water (1 drop) during 
which time a large amount of H2 was released. Then a portion of water (15 mL) was 
added and the mixture extracted with ethyl acetate (4 x 25 mL). The combined organic 
layers were washed with sat. aq. NaHCO3 (25 mL) and brine (25 mL), then dried over 
MgSO4. After evaporation of the ethyl acetate a yellowish crude crystalized giving 20 
(0.088 g; 0.36 mmol; 48 %). [α]D20 -57.5º (c = 0.4, CHCl3); νmax(Nujol, cm-1) 3320, 1670, 
1604, 1591, 1530. 1H NMR (δH, 300 MHz, CDCl3) 3.45 (1H, dd, J 18.3, 1.2 Hz, H-8), 
3.71 (1H, d, J 10.5 Hz, H-4), 3.90 (dd, J 2.7, 11.1 Hz, H-4), 4.00 (1H, dd, J 18.3, 1.2 Hz, 
H-8), 4.56 (1H, d, J 10.5Hz, H-2), 4.66(1H, bs, H-5), 4.69 (d, J 10.5 Hz, H-2) , 6.07 (2H, 
bs, H-6+ H-7), 7.04 (t, J 7.2 Hz, CH, Ph), 7.31 (2H, t, J 7.2 Hz, CH, Ph), 7.49 (2H, d, J 
7.2 Hz, CH, Ph), 8.00 (1H, bs, NH) ppm. 13C NMR (δC, 100 MHz, CDCl3) 44.4 (C-5), 50.7 
(C-8), 66.7 (C-4), 86.3 (C-2), 118.7 (CH, Ph), 122.9 (CH, Ph), 127.8 (C-7 or C-6), 128.9 
(C-6 or C-7), 128.9 (C-H, Ph), 138.5 (Cq, Ph), 153.1 (C=O) ppm. HRMS (FAB): Calcd for 
C13H16N3O2, 246.124252; Found, 246.124172. 
 
Synthesis of (S)-6-(hydroxymethyl)-N-phenyl-2,3-dihydropyridazine-1(6H)-
carboxamide 21 
To the ester (-)-11 (0.15 g; 0.5 mmol) solubilized in dry THF (10 mL) was added LiAlH4 
1M in THF (15 eq.; 13.5 mL), freshly open, at 0 ºC. The mixture was kept under stirring 
for 4h at rt. The reaction was quenched by a drop of water followed by 2 drops of aq. 
NaOH 15 % and another drop of water during which time a large amount of H2 was 
released. Then a portion of water (40 mL) was added and the mixture extracted with 
ethyl acetate (5 x 40 mL). The combined organic layers were washed with sat. aq. 
NaHCO3 (50 mL) and brine (50 mL), then dried over MgSO4. After evaporation of the 
ethyl acetate a yellowish crude was obtained from which crystalized a solid (0.10 g; 0.43 
mmol; 86 %). [α]D20 -150.8º (c = 0.4, CHCl3); νmax(Nujol, cm-1) 3359, 3268, 3058, 1636, 
1601, 1592, 1536. 1H NMR (δH, 300 MHz, CDCl3) 3.30 (1H, bd, J 17.2 Hz, H-3), 3.48-
3.55 (1H, m, H-3), 3.75 (1H, dd, J 10.8, 5.2 Hz, CH2OH), 3.95 (1H, dd, J 11.2, 3.2 Hz, 
CH2OH), 4.20 (1H, dd, J 11.2, 2.4 Hz, OH), 4.78 (1H, bs, H-6), 5.83 (1H, dm, J 8.4 Hz, 
H-4 or H-5), 6.13 (1H, dm, J 8.4 Hz, H-4 or H-5), 7.02 (1H, t, J 7.6 Hz, CH, Ph), 7.30 
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(2H, t, J 7.6 Hz, CH, Ph), 7.47 (2H, d, J 7.6 Hz, CH, Ph), 8.60 (1H, bs, NH) ppm. 13C 
NMR (δC, 100 MHz, CDCl3) 45.3 (C-6), 50.7 (C-3), 65.1 (CH2OH), 122.7 (CH, Ph), 124.5 
(C-4 or C-5), 128.3 (C-5 or C-4), 128.9 (CH, Ph), 138.7 (Cq, Ph), 155.0 (C=O) ppm. 
HRMS (FAB): Calcd for C12H16N3O2, 234.124432; Found, 244.124252. 
 
Synthesis of (4R,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-N-
phenylhexahydropyridazine-1-carboxamide (-)-22 
To a solution of (-)-13 (0.06 g; 0.18 mmol) in dry THF (8 mL) was added at 0 ºC a 
solution of LiAlH4 1M in THF (7 eq.; 2.51 mL). The reaction mixture stirred for 3 h at rt, 
then the quenching was followed by sequential addition of 1 drop of water, one drop of 
aq. NaOH 15% and water (20 mL). The aqueous solution was extracted with ethyl 
acetate (6 x 60 mL). The organic layers were combined, dried and evaporated giving an 
oil that was submitted to PLC (DCM/ methanol 10%) giving the title compound (-)-22 
(0.014 g; 0.05 mmol, 29 %). [α]D20 -54.4º (c = 0.6, methanol). νmax(neat, cm-1) 3346, 
2925, 1656, 1592, 1534. 1H NMR (δH, 400 MHz, CDCl3) 2.92 (1H, dt, J 1.2, 14.8 Hz, H-
3), 3.32 (1H, dd, J 14.8, 2.0 Hz, H-3), 3.69-3.73 (1H, m, H-6), 3.82 (1H, dd, J 12.0, 4.8 
Hz, CH2OH), 3.90-3.92 (1H, m, H-4), 4.11(1H, dd, J 12.2, 9.0 Hz, CH2OH), 4.44-450 
(1H, m, H-5), 7.19-7.43 (5H, m, Ph); 13C NMR (δC, 100 MHz, CDCl3) 46.4 (C-3), 56.1 (C-
5), 59.0 (CH2OH), 64.8 (C-6), 66.2 (C-4), 121.5 (CH, Ph), 125.0 (CH, Ph), 129.1 (CH, 
Ph), 138.0 (Cq, Ph), 153.6 (C=O) ppm. HRMS (FAB): Calcd for C12H18N3O4, 268.1219; 
Found, 268.1222. 
 
Synthesis of (4S,5S,6S)-4,5-dihydroxy-6-(hydroxymethyl)-N-
phenylhexahydropyridazine-1-carboxamide (+)-22 
To a solution of (+)-13 (0.12 g; 0.36 mmol) in dry THF (10 mL) was added at 0 ºC a 
solution of LiAlH4 1M in THF (7 eq.; 5.03 mL). The reaction mixture stirred for 1.5 h at rt, 
then the quenching was followed by sequential addition of 1 drop of water, one drop of 
aq. NaOH 15% and water (50 mL). The aqueous solution was extracted with ethyl 
acetate (10 x 40 mL). The organic layers were combined, dried and evaporated giving 
an oil that was submitted to PLC (DCM/ methanol 10%) giving the title compound (+)-22 
(0.010 g; 0.04 mmol, 10 %). [α]D20 +51.3º (c = 1, methanol).  
 
Measurement of glycosidase inhibition 
α-Glucosidase from bakers’ yeast (EC 3.2.1.20, Sigma G-5003) and β-glucosidase from 
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almonds (EC 3.2.1.21, Sigma G-0395) were used as model glycosidases. Enzyme 
assays were conducted in 96 wells Nunc plates using 4-nitrophenyl α-D-glucopyranoside 
or 4-nitrophenyl β-D-glucopyranoside as substrates, in phosphate buffer 100 mM, pH 7.0 
or citrate buffer 100 mM, pH 5.0 at 25 ºC. A range of substrate concentrations from 3.3 x 
10-5 M to 2.0 x 10-3 M (11 different concentrations), in a final volume of 300 µL, was 
tested using 0.2 units/mL of β-glucosidase or 0.15 units/mL of α-glucosidase, in the 
absence and in the presence of inhibitor ((+)- and (-)-22, 5 x 10-6 M and 10 x 10-6 M). 
Blanks were set containing all reaction components but enzyme. All assays were 
performed in triplicate. 
The formation of 4-nitrophenol was monitored for 20 min at 25 ºC, measuring the 
absorbance (1 reading each minute) at 400 nm. A value of εl = 787.73 M-1 (pH 7.0) or 
28.29 M-1 (pH 5.0), determined in the same conditions as used for the enzyme assays, 
was used to convert absorvance into product concentration. Initial velocities were 
calculated from the slopes of the Abs vs time graphs for each concentration of substrate 
and used to construct Michaelis-Menten plots. The kinetic parameters KM and Vmax 
were determined by fitting the experimental results to a rectangular hyperbole using the 
Origin 8 Graph Pad and by Lineweaver-Burk analysis. The inhibition type was 
established as competitive for all enzymes and inhibitors tested, using 2 different 
concentrations of inhibitors (in duplicate) and by examining the Lineweaver-Burk plot. 
For each inhibitor concentration, individual Ki values were obtained using the expression 
for competitive inhibition (Ki= [I]/((KMapp/KM)-1)) were KM and KMapp represent the 
Michaelis-Menten constant in the absence and in the presence of inhibitor, respectively. 
Reported Ki values are expressed as average of 2 independent Ki determinations.  
 
Structural molecular modelling studies 
Structural enzyme-compound complexes and theoretical binding free energy of (-)-2, (+)-
2, and 22 towards yeast a-glucosidase structure were done with computational docking 
methodologies using AUTODOCK 4.19 The modelling of the enzyme-compound 
complexes with almond b-glucosidase was not calculated, because to the best of our 
knowledge, no structure or protein sequence is available. In the docking calculations, all 
possible torsions of the compounds were set flexible except the amide bonds in both 
enantiomers of compound 22. The protonation state of the amine N-1 and N-2 of the 
compounds was set neutral, in agreement with previous NMR evidences.20 The grid for 
probe-target energy calculations was placed with its centre at the enzyme-binding site. 
 21 
The docking grid size was 42x40x42 grid points with 0.375 Å spacing. For each ligand, 
20 runs using the Lamarckian genetic algorithm with 150 individuals in each population 
were carried out. The maximum number of generations was set to 27×103 and the 
maximum number of energy evaluations to 5×106. The resulting docking solutions were 
clustered using AUTODOCK with a structural root mean square deviation cut-off of 1 Å. 
Since no experimental structure exists for the yeast α-glucosidase enzyme, a theoretical 
structural model of this enzyme was derived using MODELLER,21 employing the crystal 
structure of isomaltase from Saccharomyces cerevisiae structure (PDB ID:3A4A)13 as 
template. Isomaltase and a-glucosidase from Saccharomyces cerevisiae share 72% 
sequence similarity. 20 models were generated using an initial alignment between the 
isomaltase and a-glucosidase enzyme sequences. The model with the lowest objective 
function21 was chosen and its quality was evaluated based on its stereochemistry given 
by Procheck.22 A high quality model of the yeast a-glucosidase enzyme was obtained 
with no residues in disallowed regions in the Ramachandran plot. The protonation states 
of the acidic and basic residues were set to their standard state found in aqueous 
solution at pH 7. 
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